Aerovate’s stock craters af­ter PAH drug fails Phase 2 study

Aerovate Ther­a­peu­tics’ mid-stage treat­ment for pul­monary ar­te­r­i­al hy­per­ten­sion failed to mean­ing­ful­ly im­prove pa­tients’ blood pres­sure com­pared to place­bo across three dos­es, send­ing the com­pa­ny’s shares …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER